 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | HIV vaccine vCP2438 / Sanofi, GSK, ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Journal: Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. (Pubmed Central) - Aug 4, 2024
Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity.
- |||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Trial completion: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - May 19, 2022
P2b, N=5407, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity. Active, not recruiting --> Completed
- || ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Trial primary completion date: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - Apr 22, 2021
P2b, N=5407, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Feb 2021 --> Sep 2021
- || ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion date, Trial primary completion date: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Jan 8, 2021
P1/2, N=160, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Feb 2021 --> Sep 2021 Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Oct 2019 --> Jul 2020
- || ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - Aug 10, 2020
P2b, N=5407, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Oct 2019 --> Jul 2020 Trial completion date: Jul 2022 --> Aug 2021 | Trial primary completion date: Jul 2022 --> Feb 2021
- ||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Trial completion, Trial completion date: HVTN107: Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (clinicaltrials.gov) - Feb 11, 2020
P1/2, N=132, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Jul 2022 --> Aug 2021 | Trial primary completion date: Jul 2022 --> Feb 2021 Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Dec 2019
- ||| ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Nov 8, 2019
P1/2, N=160, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Dec 2019 Active, not recruiting --> Completed
- | ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Enrollment closed, Trial completion date, Trial primary completion date: HVTN107: Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (clinicaltrials.gov) - Aug 5, 2019
P1/2, N=132, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Jan 2020
- | ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Enrollment closed: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - Aug 5, 2019
P2b, N=5407, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Jan 2020 Recruiting --> Active, not recruiting
- || ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - Jun 21, 2019
P2b, N=5400, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial completion date: Jul 2021 --> May 2022 | Trial primary completion date: Jul 2021 --> May 2022
- |||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion, Trial completion date, Trial primary completion date: A Safety and Immune Response Study of 2 Experimental HIV Vaccines (clinicaltrials.gov) - Apr 22, 2019
P1/2, N=252, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Jul 2021 --> May 2022 | Trial primary completion date: Jul 2021 --> May 2022 Active, not recruiting --> Completed | Trial completion date: Jan 2017 --> Aug 2018 | Trial primary completion date: Jan 2017 --> Aug 2018
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Enrollment closed: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Oct 22, 2018
P1/2, N=160, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Jan 2017 --> Aug 2018 | Trial primary completion date: Jan 2017 --> Aug 2018 Recruiting --> Active, not recruiting
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Enrollment change: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Sep 28, 2018
P1/2, N=160, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=320 --> 160
- |||| ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Enrollment open: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Jan 23, 2018
P1/2, N=320, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=320 --> 160 Not yet recruiting --> Recruiting
- ||| ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial initiation date, Trial primary completion date: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Nov 13, 2017
P1/2, N=320, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Initiation date: Jun 2017 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Sep 2019
- ||||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
New P1/2 trial: HVTN107: Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (clinicaltrials.gov) - Sep 14, 2017
P1/2, N=132, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||||| ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
New P1/2 trial: Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59 (clinicaltrials.gov) - Apr 20, 2017
P1/2, N=320, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- || ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
Enrollment status, IO biomarker: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - Dec 28, 2016
P2b, N=5400, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Jun 2017 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Sep 2019 Enrolling by invitation --> Recruiting
- |||||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases
New P2b trial, IO biomarker: HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - Nov 21, 2016
P2b, N=5400, Enrolling by invitation, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Enrollment closed: A Safety and Immune Response Study of 2 Experimental HIV Vaccines (clinicaltrials.gov) - Dec 12, 2015
P1/2, N=252, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Recruiting Recruiting --> Active, not recruiting
- ||||| ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
New P1/2 trial, New P2 trial: A Safety and Immune Response Study of 2 Experimental HIV Vaccines (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=252, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)